Background: The opioid epidemic presses on as a significant public health issue in the U.S., with particularly high overdose death rates in the Southeast. Naloxone is the standard of care for reversing opioid overdose; however, many people who use drugs (PWUD) experience barriers to naloxone use. This cross-sectional survey study aims to describe awareness of, experience with, willingness, barriers, and distribution strategies for naloxone among PWUD in the Southeast.
Methods: Data were obtained from a larger implementation survey study. Descriptive analyses focused on N = 381 people in substance use treatment programs, syringe services programs, and sexually transmitted infection clinics who reported non-prescription opioid use in the past 12 months and completed a naloxone-related questionnaire.
Results: Most PWUD reported using opioids daily (60-62 %). 82 % had previously heard of naloxone, but only 43 % reported having received any type of training to use it. On a 5-point scale, PWUD without prior training (n = 219) reported being very willing to be trained to use naloxone on someone who overdoses (Mdn=5.00, IQR=2.00). Among all PWUD, not knowing where to go for naloxone training was the only barrier to using naloxone that was endorsed with certainty (Mdn=4.00, IQR=2.00). PWUD endorsed three strategies to improve naloxone distribution, including wanting their site to offer naloxone training (Mdn=4.00, IQR=1.00), increased access to naloxone education (Mdn=4.00, IQR=1.00), and connecting people to training programs (Mdn=4.00, IQR=1.00).
Conclusion: This study suggests that improvements are still needed in the saturation of naloxone training and distribution among PWUD, including in settings that provide non-opioid related services.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drugpo.2025.104769 | DOI Listing |
Drug Alcohol Depend
February 2025
Institute of Psychiatry and Neurology, Child and Adolescent Psychiatry Clinic, Warsaw, Poland. Electronic address:
Background: The standard of care for treating opioid use disorder (OUD) during pregnancy includes either buprenorphine or methadone. Although buprenorphine-naloxone presents an alternative due to the reduced risk of misuse , evidence regarding its impact on pregnancy and infant health remains limited. This systematic review and meta-analysis aims to compare buprenorphine-naloxone vs buprenorphine alone for OUD during pregnancy, assessing gestational and neonatal outcomes.
View Article and Find Full Text PDFDrug Alcohol Depend
March 2025
Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Background And Aims: Deaths from opioid overdose are increasing in the United States (US) and distribution of the opioid antagonist naloxone is one key strategy to reduce mortality. In this cross-sectional survey, we assess the association of high-risk behaviors with possession of naloxone and knowledge of where to find it.
Setting And Participants: 5663 adults entering treatment for opioid use disorder at facilities throughout the US during the calendar year 2022 were surveyed.
Int J Drug Policy
March 2025
University of Washington Medicine, Department of Psychiatry & Behavioral Sciences, Addictions, Drug & Alcohol Institute, Seattle, WA, USA. Electronic address:
Background: The opioid epidemic presses on as a significant public health issue in the U.S., with particularly high overdose death rates in the Southeast.
View Article and Find Full Text PDFBackground: There were 2227 drug-related deaths in Germany in 2023, corresponding to a rise of 12% over the previous year and a doubling over the course of a decade. Approximately 60% of these deaths were related to opioid consumption. In this narrative review, we discuss whether take-home naloxone (THN) might lower the mortality of persons with opioid dependency.
View Article and Find Full Text PDFJ Opioid Manag
March 2025
Stewardship and Clinical Appropriateness, Saskatchewan Health Authority, Regina, Sas-katchewan, Canada. ORCID: https://orcid.org/0009-0005-2332-3923.
Objective: To develop and implement a customized clinical decision support system (CDSS) in an under-resourced health region aimed at promoting appropriate and safe opioid prescribing.
Design: The Pharmaceutical Automated Reporting (PAR) tool integrates inpatient prescription data from BDM Pharmacy (version 10) and categorizes patient information using predefined logic. It operates with Python (version 3.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!